An advanced methicillin-resistant Staphylococcus aureus (MRSA) detection PCR approach targeting SCCmec-orfX along with mecA and mecC was evaluated for S. aureus and coagulase-negative staphylococci. The possession of mecA and/or mecC was correctly confirmed in all cases. All methicillin-susceptible S. aureus strains (n ‫؍‬ 98; including staphylococcal cassette chromosome mec element [SCCmec] remnants) and 98.1% of the MRSA strains (n ‫؍‬ 160, including 10 mecC-positive MRSA) were accurately categorized.
R
apid methicillin-resistant Staphylococcus aureus (MRSA) tests are based upon either the multiple-locus approach, which targets both the resistance determinant mecA and an S. aureus species-specific target, or the single-locus approach that targets the junction between the staphylococcal cassette chromosome mec element (SCCmec) and orfX. The high diversity of SCCmec and its presence in clinically relevant coagulase-negative staphylococcal (CoNS) species may lead to false-positive and/or false-negative results in both approaches, depending on the target structures (1, 2) . Hence, combining the two target strategies might help overcome some of the detection and interpretation disadvantages of currently available assays (3) . In addition, detection of the recently reported mecA homologue, designated mecC, should be included (4) (5) (6) (7) (8) .
This report describes the evaluation of an advanced rapid MRSA assay that includes primers and probes for the detection of mecA and mecC along with the detection of the SCCmec-orfX junction. In addition to the SCCmec types I to IV (including subtype IVa), and V, which were already covered by the previous version, the Xpert MRSA Gen 3 assay also detects SCCmec types VI to XI (package insert; Xpert MRSA Gen 3, Cepheid, 2014).
Using the GeneXpert automatic system (Cepheid, Sunnyvale, CA), the Xpert MRSA Gen 3 PCR assay (Cepheid) was tested on a total of 308 isolates comprising clinical, type, and reference strains, including 17 staphylococcal species and subspecies (S. aureus, n ϭ 258; CoNS, n ϭ 50) ( Table 1) . At the time of the study, the Xpert MRSA Gen3 assay was designated research use only (RUO). The current regulatory status of this assay is in vitro diagnostic use only in the CE market. All isolates were recovered from clinical specimens during the course of several German and Belgian multicenter studies (9) (10) (11) (12) (13) (14) (15) (16) . Of these, the mecA-positive MRSA strains (n ϭ 150) comprised the 50 most prevalent S. aureus protein A gene (spa) types found in Germany (12) ( Table 1) . The mecC-positive MRSA strains (n ϭ 10) were collected in Germany and the Netherlands and exhibited six different spa types (6, 12, 17) (Table 1) . Additionally, 98 methicillin-susceptible S. aureus (MSSA) isolates covering 70 spa types were tested, including 10 isolates known to give false-positive results in the previous version of the test (Xpert MRSA assay), and four previously determined SCCmec "dropout" strains, i.e., former MRSA strains that had lost major parts of the SCCmec element, including the mec genes, but still carry short remains, which might serve as a primer target in single-locus PCR approaches (9, 16) (see Table S1 in the supplemental material). Finally, 25 MR-CoNS and 25 MS-CoNS strains comprising 16 species and subspecies were tested (Table 1) . Species identification, detection of mecA and mecC, and SCCmec typing were done as described previously (6, (18) (19) (20) (21) .
To mimic the in vivo situation, 1.5 ϫ 10 4 bacterial cells were used from a fresh overnight culture in 100 l and transferred to the test cartridge. This was followed by application of the assay protocol as indicated in the Xpert MRSA Gen 3 package insert. The interpretation of the assay results and categorization as MRSA were done as recommended by the manufacturer (with "MRSA detected" meaning that both the SCCmec-orfX and mecA-mecC targets tested positive, and "MRSA not detected" meaning that one or both of the SCCmec-orfX and mecA-mecC targets tested negative). To solve discrepant results, whole-genome sequencing (WGS) was performed as recently described (22) . The resulting raw reads were mapped to the SCCmec-orfX regions of the respective SCCmec type of the reference genomes (see Table S2 in the supplemental material) after quality trimming using the BWA algorithm, with default parameters, implemented in the SeqSphere ϩ software version 2.3 (Ridom, Münster, Germany).
Overall, 157/160 (98.1% positive agreement) of the MRSA strains were correctly categorized by the novel assay. While all 10 mecC-positive strains were detected and classified as MRSA, 3 (2.0%) of the 150 mecA-positive MRSA strains were falsely categorized as MSSA due to missing amplification of the SCCmec-orfX junction (Table 1) . Another assay targeting the SCCmec-orfX junction (BD Max MRSA XT kit; BD Diagnostics, Quebec, Canada) likewise failed (not shown). The unequivocal possession of the mecA gene of these strains was reviewed by applying a further molecular assay (GenoType MRSA; Hain Lifescience, Nehren, Germany; data not shown). WGS did not show sequence variations within orfX compared to published sequences of respective S. aureus reference strains. Two of these isolates belonged to spa type t004 (sequence type 45 [ST45]) and carried SCCmec type IV. The orfX-SCCmec junction of both isolates showed a 52-kb deletion compared to S. aureus CA-347 beginning 326 bp downstream of orfX. For the third isolate (spa type t003, ST225, SCCmec type III), no considerable sequence variants were found within 3.5 kb downstream of orfX compared to S. aureus strains N315 and MW2.
All 98 MSSA strains tested showed negative results for mecAmecC amplification (100% negative agreement) and hence were correctly categorized as MSSA (see Table S1 in the supplemental material), similar to in a recent prospective study (23) . Twentyseven MSSA strains showed positive results in SCCmec-orfX junction testing, including those previously characterized as SCCmec remnant strains, and eight of the 10 isolates tested false positive in the previous version of the Xpert MRSA PCR assay (see Table S1 ). The four SCCmec remnant strains belonged to spa types t011, t038, and t068 (n ϭ 2). Other SCCmec-orfX junction-positive MSSA strains were characterized by spa types t002, t008, t216, t364, t369, t5160, and t6752 or belonged to the spa clonal complex 127 (spa-CC127) (t127, t177, and t948) (see Table S1 ). The assay detected the mecA and mecC genes correctly in all CoNS.
The detection of mecC-positive MRSA is a major advantage of the Xpert MRSA Gen 3 PCR assay. Diagnostics were challenged by the recent discovery of the mecA LGA251 (mecC) gene as part of a novel SCCmec XI element in S. aureus (4, 5) and CoNS (24) (25) (26) . With the spread of mecC-harboring MRSA (4-7, 12, 27-32) , the absence of the mecA gene alone can no longer be considered a reliable genetic marker to exclude MRSA. The failure in conventional mecA detection assays to detect mecC results in inconsistent results in comparison to those with phenotypic susceptibility tests (4-6). Besides various in-house PCR procedures (4-6, 27, 33), another commercially available multiplex PCR, based upon a multiple-locus detection strategy, was recently shown to be able to detect mecC-positive MRSA (10). Moreover, both the genetic diversity of the strain background and the occurrence of mecC-harboring staphylococci in livestock, wildlife, and environmental sources are worrisome (7, (34) (35) (36) (37) (38) (39) .
The combined detection of mecA and mecC with the SCCmecorfX junction represents a second major advantage. It overcomes the problem due to mecA-and mecC-negative remnants of the SCCmec element, which may cause false-positive results (16, (40) (41) (42) (43) (44) . Outbreaks with SCCmec remnant MSSA isolates may result in medical and economic burden due to unjustified MRSA precaution measures (45) . The inclusion of the mecA and mecC genes as targets overcomes this source of misinterpretation. All four SCCmec remnant strains included were categorized as MSSA.
In the case of the cooccurrence of an MR-CoNS and an MRSA not detected, one or both of the SCCmec-orfX and mecA and/or mecC targets tested negative. c Including more frequently encountered (t001, t002, t003, t004, t011, t008, t014, t020, t022, t024, t032, t034, t045, t264, t463, t1227, t2373, t4217, t4881, and t8374, each n ϭ 6) and rarely occurring (t012, t015, t030, t037, t038, t041, t044, t063; t114, t127, t151, t223, t318, t379, t437, t481, t504, t535, t578, t634, t651, t785, t849, t1107, t1282, t2369, t4417, t6736, t7391, and t8380, each n ϭ 1) MRSA spa types in Germany. SCCmec types I (n ϭ 7), II (n ϭ 57), III (n ϭ 2), IV (n ϭ 70) and V (n ϭ 13) were detected; one isolate was nontypeable. In conclusion, the inclusion of mecA and mecC as targets closed a gap in the molecular detection of MRSA and minimized the risk of false-positive interpretation as MRSA due to SCCmec remnant isolates. The evaluated MRSA assay challenged by a large collection of German and Belgium clonal MRSA lineages was able to detect the mecA and mecC genes, respectively, of all strains included and correctly categorized the vast majority of MRSA and all non-MRSA strains.
Nucleotide sequence accession number. The raw reads of the three isolates (RUO83 [t004], RUO140 [t003], and RUO159 [t004]) were submitted to the European Nucleotide Archive (http://www.ebi .ac.uk/ena/) under study accession no. PRJEB10686.
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